LACK OF IMPACT OF BASELINE RESISTANCE-ASSOCIATED VARIANTS (RAVS) ON TREATMENT OUTCOME IN THE AVIATOR STUDY WITH ABT-450/R, ABT-333 AND ABT-267, +/- RIBAVIRIN

被引：6

|

作者：

Krishnan, P. ^{[1
]}

Tripathi, R. ^{[1
]}

Irvin, M. ^{[1
]}

Beyer, J. ^{[1
]}

Reisch, T. ^{[1
]}

Schnell, G. ^{[1
]}

Xie, W. ^{[1
]}

Zhou, X. ^{[1
]}

Larsen, L. ^{[1
]}

Kofron, J. ^{[1
]}

Cohen, D. ^{[1
]}

Podsadecki, T. ^{[1
]}

Pilot-Matias, T. ^{[1
]}

Collins, C. ^{[1
]}

机构：

[1] AbbVie Inc, N Chicago, IL USA

来源：

JOURNAL OF HEPATOLOGY | 2014年 / 60卷 / 01期

关键词：

D O I：

10.1016/S0168-8278(14)61390-8

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

P1230

引用

收藏

页码：S498 / S498

页数：1

相关论文

共 33 条

[31] 12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333+RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS
Poordad, F.
Lawitz, E.
Kowdley, K. V.
Everson, G. T.
Freilich, B.
Cohen, D.
Siggelkow, S.
Heckaman, M.
Menon, R.
Pilot-Matias, T.
Podsadecki, T.
Bernstein, B.
JOURNAL OF HEPATOLOGY, 2012, 56 : S549 - S550
[32] TURQUOISE-II: Trends in Liver Fibrosis Testing, Hepatic Synthetic Function, and Platelet Counts at Baseline and 12 Weeks After Treatment With ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin in HCV Genotype 1-Infected Patients with Cirrhosis
Shiffman, Mitchell L.
Kowdley, Kris V.
Zeuzem, Stefan
Mutimer, David J.
Bourliere, Marc
Berg, Thomas
Lee, Samuel S.
Lovell, Sandra S.
Canizaro, Leticia
Trinh, Roger
Neff, Guy
Kwo, Paul Y.
HEPATOLOGY, 2014, 60 : 1152A - 1152A
[33] Low Relapse Rate Leads to High Concordance of Sustained Virologic Response (SVR) at 12 Weeks With SVR at 24 Weeks After Treatment With ABT-450/Ritonavir, Ombitasvir, and Dasabuvir Plus Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection in the AVIATOR Study
Poordad, Fred
Agarwal, Kosh
Younes, Ziad
Cohen, Daniel
Xie, Wangang
Podsadecki, Thomas
CLINICAL INFECTIOUS DISEASES, 2015, 60 (04) : 608 - 610

← 1 2 3 4 →